Alfaxalone - Drawbridge Pharmaceuticals

Drug Profile

Alfaxalone - Drawbridge Pharmaceuticals

Alternative Names: PHAX-001; Phaxan

Latest Information Update: 20 May 2016

Price : $50

At a glance

  • Originator Drawbridge Pharmaceuticals
  • Class General anaesthetics
  • Mechanism of Action Central nervous system modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Anaesthesia

Most Recent Events

  • 17 May 2016 Phase-I development is ongoing in Australia
  • 01 Dec 2013 Phase-I clinical trials in Anaesthesia in Australia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top